Nicola Zamboni

ETH Zurich — Switzerland

Biochemistry, Genetics and Molecular Biology · Life Sciences

68h-index20.8kcitations494works1.02yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(88), Metabolomics and Mass Spectrometry Studies(76), Cancer, Hypoxia, and Metabolism(65), Mitochondrial Function and Pathology(53), Virus-based gene therapy research(45)

Publications494 total

Chemotherapy-driven intestinal dysbiosis and indole-3-propionic acid rewire myelopoiesis to promote a metastasis-refractory state

Nature Communications·2025Open Access

Multi-omics analysis reveals metabolic diversity underlying endothelial cell functions

Life Science Alliance·2025Open Access

Vacuolar-type H+-ATPase-mediated extra-organellar buffering resolves mitochondrial dysfunction

Nature Communications·2025Open Access

A Perspective on Unintentional Fragments and Their Impact on the Dark Metabolome, Untargeted Profiling, Molecular Networking, Public Data, and Repository Scale Analysis

2 cited

JACS Au·2025· 2 citedOpen Access

Suppl. Figure S3 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S10 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S9 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl Figure S4 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Table ST1 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S5 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S13 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Table ST4 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S12 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S2 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S6 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S14 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Table ST9 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S15 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Table ST7 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl Figure S11 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

page 1 of 25Next →

Frequent Co-authors

Uwe Sauer(19), Tobias Fuhrer(8), Jennifer C. Ewald(5), Paola Picotti(4), Matthias Heinemann(4), Johan Auwerx(4), Joerg M. Buescher(3), Sarah‐Maria Fendt(3), Werner J. Kovacs(3), Mattia Zampieri(3), Andreas Kuehne(3), Sébastien Dubuis(3), Ruedi Aebersold(3), Daniel C. Sévin(3), Maria Zimmermann‐Kogadeeva(2), Peter Mirtschink(2), Hannes Link(2), Jens Nielsen(2), Davide D’Amico(2), Bart Ghesquière(2)